1-6 of 6
Louis Lombardo
Close
Sort by
Journal Articles

Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2

Ashok V Purandare, PhD, Animesh Pardanani, MBBS, PhD, Theresa McDevitt, Marco Gottardis, PhD, Terra Lasho, MT, (ASCP), Dan You, Louis Lombardo, Becky Penhallow, Ragini Vuppugalla, George Trainor, PhD, Ayalew Tefferi, MD, Matthew Lorenzi, PhD
Journal: Blood
Blood (2010) 116 (21): 4112.
https://doi.org/10.1182/blood.V116.21.4112.4112
Published: 2010
Journal Articles

In Vitro Cardiotoxicity Potential Comparative Assessments of Chronic Myelogenous Leukemia Tyrosine Kinase Inhibitor Therapies: Dasatinib, Imatinib and Nilotinib.

Wendy J. Freebern, PhD, Hengsheng S. Fang, Martin D. Slade, Susan Wells, Jennifer Canale, John Megill, Branka Grubor, PhD, DVM, Hong Shi, Anthony Fletcher, DVM, Louis Lombardo, Paul Levesque, Francis Y. Lee, Vito G. Sasseville, PhD, DVM
Journal: Blood
Blood (2007) 110 (11): 4582.
https://doi.org/10.1182/blood.V110.11.4582.4582
Published: 2007
Journal Articles

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Rajeev Bhide, PhD, Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, B.Sc, Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, David Kan, B.Sc, Roger Luo, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Robert Wild, PhD, Robert Borzilleri, PhD, Louis Lombardo, PhD
Journal: Blood
Blood (2005) 106 (11): 1994.
https://doi.org/10.1182/blood.V106.11.1994.1994
Published: 2005
Journal Articles

The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.

John S. Tokarski, Ph.D., John Newitt, Ph.D., Francis Y. Lee, Ph.D., Louis Lombardo, Ph.D., Robert Borzilleri, Ph.D., Kevin Kish, Dianlin Xie, Yaqun Zhang, Janet D. Cheng, Ph.D., Susan E. Kiefer, Chieh Ying J. Chang, Herbert E. Klei, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 553.
https://doi.org/10.1182/blood.V104.11.553.553
Published: 2004
Journal Articles

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.

Feng Roger Luo, Ph.D., Zheng Yang, Ph.D., Amy Camuso, B.S., Richard Smykla, B.S., Stephen Castenada, B.S., Christine Flefleh, B.S., Krista Fager, M.S., Ivan Inigo, B.S., David Kan, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, M.S., Robert Wild, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 1987.
https://doi.org/10.1182/blood.V104.11.1987.1987
Published: 2004
Journal Articles

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

Robert Wild, Ph.D., Stephen Castaneda, B.S., Christine Flefleh, B.S., Krista Fager, B.S., Ivan Inigo, B.S., David Kan, B.S., Richard Smykla, B.S., Amy Camuso, B.S., Kelly McGlinchey, B.S., Mei-Li Wen, B.S., Feng Roger Luo, Ph.D., Robert Borzilleri, Ph.D., Louis Lombardo, Ph.D., Robert Kramer, Ph.D., Francis Y. Lee, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 1988.
https://doi.org/10.1182/blood.V104.11.1988.1988
Published: 2004